Synovial Fluid and Joint Sepsis
滑液和关节败血症
基本信息
- 批准号:10183167
- 负责人:
- 金额:$ 44.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:Acute suppurative arthritis due to bacteriaAmikacinAnimal Disease ModelsAnti-Bacterial AgentsAntibiotic TherapyAntibioticsArthritisBacteriaBiochemicalCharacteristicsClinicalCoagulation ProcessDataDebridementDiagnosisEffectivenessEnsureExcisionExhibitsFamily suidaeFibrinHumanIn SituIn VitroInfectionIrrigationJoint CapsuleJointsLocal Anti-Infective AgentsMediatingMetabolicMethicillinMicrobial BiofilmsMicrobiologyMicrobubblesMicroscopicModelingMusculoskeletal DiseasesOperative Surgical ProceduresOrthopedicsPainPatientsPermeabilityPharmaceutical PreparationsPhysicsPreventionProtease InhibitorProteinsRecurrenceRuptureStaphylococcus aureusStaphylococcus epidermidisStructureSurfaceSurgeonSynovial FluidSynovial jointTestingTissuesTreatment EfficacyUltrasonographyaggressive therapyantimicrobialbarrier to carebasecombatcostcrosslinkeffective therapyin vivojoint destructionjoint infectionjoint injurymethicillin resistant Staphylococcus aureusmortalitynecrotic tissueneutrophilnovel therapeuticsporcine modelpreventprotein aggregationsepticsuccess
项目摘要
ABSTRACT
In 2013, more than 20,000 patients in the US were diagnosed with joint infection. Despite surgical
intervention with debridement of necrotic tissue, aggressive lavage with antiseptic solutions, and systemic
antibiotic treatment, the mortality rate exceeds 11% and recurrence is common. Furthermore, the aggressive
treatments damage the joint ensuring later arthritis. Once bacteria access the joint capsule, our preliminary
data suggest that bacterial contaminants become recalcitrant to antibiotic treatments due to formation of large
bacterial aggregates that can be floating or loosely associated with tissues. We propose to develop new
treatments that disrupt and prevent re-formation of bacterial aggregates in septic joints to allow effective
antibacterial treatment. To attack this problem, we propose three specific aims: Specific Aim 1: To inhibit
bacterial aggregate formation in synovial fluid through treatment with drugs that alter protein aggregation. We
hypothesize that inhibition of aggregation will allow antibiotic access and increased effectiveness. Specific Aim
2: To permeabilize synovial fluid aggregates using ultrasound-mediated microbubble rupture in an ex vivo
model of the joint. We hypothesize that microbubble cavitation will permeabilize aggregates to increase
antibiotic efficacy towards bacteria within the clump. Specific Aim 3: To eradicate joint infection, in vivo,
through combined microbubble/drug/antibiotic treatments. We will test the hypothesis that joint infections
may be treated more effectively by the local application of microbubble cavitation in the presence of agents
from Specific Aim 1 and amikacin. To attack this problem, we have assembled a team of experts in orthopaedic
infection, animal models of disease, ultrasound physics, musculoskeletal disease together with a practicing
orthopaedic surgeon specializing in joint infection. The success of our proposed approach will lead to higher
treatment success rates, so that the pain, cost, suffering and mortality associated with joint infections will be
markedly reduced.
摘要
2013年,美国有超过20,000名患者被诊断患有关节感染。尽管进行了手术
通过坏死组织清创术、用防腐剂溶液积极灌洗和全身性
抗生素治疗,死亡率超过11%,复发是常见的。此外,侵略性
治疗会损害关节,从而导致关节炎。一旦细菌进入关节囊,
数据表明细菌污染物由于形成大的
细菌聚集体可以漂浮或松散地与组织结合。我们建议开发新的
破坏和防止脓毒症关节中细菌聚集体的重新形成以允许有效的
抗菌处理为了解决这个问题,我们提出了三个具体目标:具体目标1:
通过使用改变蛋白质聚集的药物治疗,滑液中的细菌聚集体形成。我们
假设聚集抑制将允许抗生素进入并增加有效性。具体目标
2:使用超声介导的微泡破裂在体外透化滑液聚集体
关节的模型。我们假设微泡空化将渗透聚集体,以增加
对菌丛内的细菌的抗生素效力。具体目标3:在体内根除关节感染,
通过微泡/药物/抗生素联合治疗。我们将检验关节感染
可以通过在试剂存在下局部应用微泡空化来更有效地治疗
特效药1和阿米卡星为了解决这个问题,我们召集了一个骨科专家小组,
感染,疾病的动物模型,超声物理学,肌肉骨骼疾病连同实践
专攻关节感染的整形外科医生。我们提出的方法的成功将导致更高的
治疗成功率,因此,与关节感染相关的疼痛,费用,痛苦和死亡率将
明显减少。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A Platelet-Rich Plasma-Derived Biologic Clears Staphylococcus aureus Biofilms While Mitigating Cartilage Degeneration and Joint Inflammation in a Clinically Relevant Large Animal Infectious Arthritis Model.
- DOI:10.3389/fcimb.2022.895022
- 发表时间:2022
- 期刊:
- 影响因子:5.7
- 作者:Gilbertie, Jessica M.;Schaer, Thomas P.;Engiles, Julie B.;Seiler, Gabriela S.;Deddens, Bennett L.;Schubert, Alicia G.;Jacob, Megan E.;Stefanovski, Darko;Ruthel, Gordon;Hickok, Noreen J.;Stowe, Devorah M.;Frink, Alexa;Schnabel, Lauren V.
- 通讯作者:Schnabel, Lauren V.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Noreen J Hickok其他文献
Noreen J Hickok的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Noreen J Hickok', 18)}}的其他基金
The joint environment and periprosthetic joint infection
关节环境与假体周围感染
- 批准号:
10744580 - 财政年份:2023
- 资助金额:
$ 44.1万 - 项目类别:
EXON-SPECIFIC FIBRONECTIN ISOFORMS AND CHONDROGENESIS
外显子特异性纤连蛋白异构体和软骨形成
- 批准号:
6375092 - 财政年份:2000
- 资助金额:
$ 44.1万 - 项目类别:
EXON-SPECIFIC FIBRONECTIN ISOFORMS AND CHONDROGENESIS
外显子特异性纤连蛋白异构体和软骨形成
- 批准号:
6648493 - 财政年份:2000
- 资助金额:
$ 44.1万 - 项目类别:
EXON-SPECIFIC FIBRONECTIN ISOFORMS AND CHONDROGENESIS
外显子特异性纤连蛋白异构体和软骨形成
- 批准号:
6511911 - 财政年份:2000
- 资助金额:
$ 44.1万 - 项目类别:
REGULATION OF HUMAN KERATINOCYTE GENE EXPRESSION BY TPA
TPA 对人类角质形成细胞基因表达的调节
- 批准号:
3162188 - 财政年份:1992
- 资助金额:
$ 44.1万 - 项目类别:
REGULATION OF HUMAN KERATINOCYTE GENE EXPRESSION BY TPA
TPA 对人类角质形成细胞基因表达的调节
- 批准号:
2080962 - 财政年份:1992
- 资助金额:
$ 44.1万 - 项目类别:
REGULATION OF HUMAN KERATINOCYTE GENE EXPRESSION BY TPA
TPA 对人类角质形成细胞基因表达的调节
- 批准号:
3162189 - 财政年份:1992
- 资助金额:
$ 44.1万 - 项目类别:
相似海外基金
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection
ORC-13661预防静脉阿米卡星治疗非结核分枝杆菌感染患者耳毒性的有效性和安全性的2期研究
- 批准号:
10426862 - 财政年份:2022
- 资助金额:
$ 44.1万 - 项目类别:
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection
ORC-13661预防静脉阿米卡星治疗非结核分枝杆菌感染患者耳毒性的有效性和安全性的2期研究
- 批准号:
10706468 - 财政年份:2022
- 资助金额:
$ 44.1万 - 项目类别:
Development of synergistic clofazimine-amikacin inhalable powders for the treatment of pulmonary Mycobacterium abscessus infections
氯法齐明-阿米卡星协同吸入粉剂治疗肺部脓肿分枝杆菌感染的研制
- 批准号:
10256328 - 财政年份:2021
- 资助金额:
$ 44.1万 - 项目类别:
PHARMACOLOGY AND TOXICOLOGY STUDIES OF AMIKACIN, TLC-ART-101, NDB-COMPOUNDS, SUTEZOLID, AND SUPPORT THE DEVELOPMENT OF MITOCHONDRIAL TOXICITY ASSAYS
阿米卡星、TLC-ART-101、NDB-化合物、舒特唑胺的药理学和毒理学研究,并支持线粒体毒性测定的开发
- 批准号:
9544404 - 财政年份:2017
- 资助金额:
$ 44.1万 - 项目类别:
IGF::OT::IGF PHARMACOLOGY AND TOXICOLOGY STUDIES OF AMIKACIN AND SUTEZOLID, AND SUPPORT THE DEVELOPMENT OF BIOMARKER AND MITOCHONDRIAL TOXICITY ASSAYS.
IGF::OT::IGF 阿米卡星和 Sutezolid 的药理学和毒理学研究,并支持生物标志物和线粒体毒性测定的开发。
- 批准号:
9362026 - 财政年份:2016
- 资助金额:
$ 44.1万 - 项目类别:
MULTIDOSE SAFETY AND TOLERABILITY LIPOSOMAL AMIKACIN IN CYSTIC
囊状阿米卡星脂质体多剂量安全性和耐受性
- 批准号:
7952078 - 财政年份:2008
- 资助金额:
$ 44.1万 - 项目类别:
MULTIDOSE SAFETY AND TOLERABILITY STUDY OF LIPOSOMAL AMIKACIN FOR INHALATION (AR
吸入用脂质体阿米卡星 (AR) 的多剂量安全性和耐受性研究
- 批准号:
7951758 - 财政年份:2008
- 资助金额:
$ 44.1万 - 项目类别:
MULTIPLE DOSE STUDY OF LIPOSOMAL AMIKACIN IN HIV SEROPOTISTIVE PATIENTS
脂质体阿米卡星在 HIV 血清阳性患者中的多剂量研究
- 批准号:
6115061 - 财政年份:1998
- 资助金额:
$ 44.1万 - 项目类别:
MULTIPLE DOSE STUDY OF LIPOSOMAL AMIKACIN IN HIV SEROPOTISTIVE PATIENTS
脂质体阿米卡星在 HIV 血清阳性患者中的多剂量研究
- 批准号:
6276296 - 财政年份:1997
- 资助金额:
$ 44.1万 - 项目类别:
RIFAMPIN, CIPROFLAXACIN, CLOFAZIMINE, ETHAMBUTOL, & AMIKACIN IN HIV+ INDIVIDUALS
利福平、环丙沙星、氯法齐明、乙胺丁醇、
- 批准号:
3785436 - 财政年份:
- 资助金额:
$ 44.1万 - 项目类别: